You are on the new improved site. You can view the old site in view-only mode here until June 27, 2026

Filter Results

Select search scope: search across all journals or within the current journal

Search this journal

Enter search terms…

Advanced search

Browse

About

About Sage
About Sage Journals
Privacy Policy
Terms of Use
Contact Us
Help

Information for

Authors
Editors
Librarians
Researchers
Reviewers
Frequently asked questions

All content on this site: Copyright © 2026 Sage Publications. All rights reserved. This website is technically supported and operated by China National Publications Import and Export (Group) Co., Ltd. 京ICP备09090397号-11

A Double-Blind,Placebo Controlled,Dose Ranging Study to Evaluate the Safety and Biological Efficacy of the Lipid-DNA Complex GR213487B in the Nasal Epithelium of Adult Patients with Cystic Fibrosis. Glaxo Wellcome Research and Development Ltd.,London,England

Human Gene Therapy

Impact Factor: 4.0

Journal Homepage Submission guidelines

Restricted access

Research article

First published online January, 1998

A Double-Blind,Placebo Controlled,Dose Ranging Study to Evaluate the Safety and Biological Efficacy of the Lipid-DNA Complex GR213487B in the Nasal Epithelium of Adult Patients with Cystic Fibrosis. Glaxo Wellcome Research and Development Ltd.,London,England

, , [...], and

Volume 9, Issue 2

https://doi.org/10.1089/hum.1998.9.2-249

Abstract

GTAB1001: A Double-Blind, Placebo Controlled, Dose Ranging Study to Evaluate the Safety and Biological Efficacy of the Lipid-DNA Complex GR213487B in the Nasal Epithelium of Adult Patients with Cystic Fibrosis.

Get full access to this article

View all access options for this article.

Browse journal

Current issue OnlineFirst All issues